Skip to main content
. 2017 May 22;17:36. doi: 10.1186/s12894-017-0226-2

Fig. 4.

Fig. 4

Median time to discontinuation according to the antimuscarinic used in combination (α-blocker and antimuscarinic, either as FDC or concomitant therapy) (a) and for α-blocker plus solifenacin (FDC vs. concomitant) combination therapy (b). CI: confidence intervals; FDC: fixed-dose combination; HR: hazard ratio; TTD: time to discontinuation